262 related articles for article (PubMed ID: 30587236)
1. PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8
Carnevalli LS; Sinclair C; Taylor MA; Gutierrez PM; Langdon S; Coenen-Stass AML; Mooney L; Hughes A; Jarvis L; Staniszewska A; Crafter C; Sidders B; Hardaker E; Hudson K; Barry ST
J Immunother Cancer; 2018 Dec; 6(1):158. PubMed ID: 30587236
[TBL] [Abstract][Full Text] [Related]
2. Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.
Hudson K; Hancox UJ; Trigwell C; McEwen R; Polanska UM; Nikolaou M; Morentin Gutierrez P; Avivar-Valderas A; Delpuech O; Dudley P; Hanson L; Ellston R; Jones A; Cumberbatch M; Cosulich SC; Ward L; Cruzalegui F; Green S
Mol Cancer Ther; 2016 May; 15(5):877-89. PubMed ID: 26839307
[TBL] [Abstract][Full Text] [Related]
3. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
4. Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.
Rewcastle GW; Kolekar S; Buchanan CM; Gamage SA; Giddens AC; Tsang KY; Kendall JD; Singh R; Lee WJ; Smith GC; Han W; Matthews DJ; Denny WA; Shepherd PR; Jamieson SMF
Oncotarget; 2017 Jul; 8(29):47725-47740. PubMed ID: 28537878
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.
Barlaam B; Cosulich S; Delouvrié B; Ellston R; Fitzek M; Germain H; Green S; Hancox U; Harris CS; Hudson K; Lambert-van der Brempt C; Lebraud H; Magnien F; Lamorlette M; Le Griffon A; Morgentin R; Ouvry G; Page K; Pasquet G; Polanska U; Ruston L; Saleh T; Vautier M; Ward L
Bioorg Med Chem Lett; 2015 Nov; 25(22):5155-62. PubMed ID: 26475521
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.
Davis RJ; Moore EC; Clavijo PE; Friedman J; Cash H; Chen Z; Silvin C; Van Waes C; Allen C
Cancer Res; 2017 May; 77(10):2607-2619. PubMed ID: 28364000
[TBL] [Abstract][Full Text] [Related]
7. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M
Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773
[TBL] [Abstract][Full Text] [Related]
8. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
Qi Z; Xu Z; Zhang L; Zou Y; Li J; Yan W; Li C; Liu N; Wu H
Nat Commun; 2022 Jan; 13(1):182. PubMed ID: 35013322
[TBL] [Abstract][Full Text] [Related]
9. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Lim EL; Cugliandolo FM; Rosner DR; Gyori D; Roychoudhuri R; Okkenhaug K
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875319
[TBL] [Abstract][Full Text] [Related]
10. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression.
Gao HF; Cheng CS; Tang J; Li Y; Chen H; Meng ZQ; Chen Z; Chen LY
Aging (Albany NY); 2020 Jan; 12(1):502-517. PubMed ID: 31913856
[TBL] [Abstract][Full Text] [Related]
11. PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8
Sun P; Zhang X; Wang RJ; Ma QY; Xu L; Wang Y; Liao HP; Wang HL; Hu LD; Kong X; Ding J; Meng LH
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34373258
[TBL] [Abstract][Full Text] [Related]
12. PI3Kα inhibitor GNE-493 triggers antitumor immunity in murine lung cancer by inducing immunogenic cell death and activating T cells.
Xue X; Ye G; Zhang L; Zhu X; Liu Q; Rui G; Geng G; Lin Y; Chen X
Int Immunopharmacol; 2024 Mar; 130():111747. PubMed ID: 38442576
[TBL] [Abstract][Full Text] [Related]
13. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
14. β-Adrenergic Signaling Impairs Antitumor CD8
Nissen MD; Sloan EK; Mattarollo SR
Cancer Immunol Res; 2018 Jan; 6(1):98-109. PubMed ID: 29146881
[TBL] [Abstract][Full Text] [Related]
15. PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
Sai J; Owens P; Novitskiy SV; Hawkins OE; Vilgelm AE; Yang J; Sobolik T; Lavender N; Johnson AC; McClain C; Ayers GD; Kelley MC; Sanders M; Mayer IA; Moses HL; Boothby M; Richmond A
Clin Cancer Res; 2017 Jul; 23(13):3371-3384. PubMed ID: 28003307
[No Abstract] [Full Text] [Related]
16. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
Yin W; Song Y; Liu Q; Wu Y; He R
Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma.
Eckerdt F; Clymer J; Bell JB; Beauchamp EM; Blyth GT; Goldman S; Platanias LC
Sci Rep; 2019 Sep; 9(1):12822. PubMed ID: 31492956
[TBL] [Abstract][Full Text] [Related]
18. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
19. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by
Abu Eid R; Ahmad S; Lin Y; Webb M; Berrong Z; Shrimali R; Kumai T; Ananth S; Rodriguez PC; Celis E; Janik J; Mkrtichyan M; Khleif SN
Cancer Res; 2017 Aug; 77(15):4135-4145. PubMed ID: 28615225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]